Maravai Q2 revenue up 8.5% to $51.4M; raises FY2026 Adj EBITDA guidance to $33-35M

MARAVAI LIFESCIENCES HOLDINGS, INC.

Q2 revenue $51.4M (+8.5% YoY); net loss narrowed to $(21.6)M from $(69.8)M; Adj EBITDA $8.7M vs $(10.4)M loss.
TriLink revenue $34.7M (+11.5% YoY) driven by Discovery mRNA and GMP consumables; Cygnus $16.8M (+2.8%).
Full year 2026 Adj EBITDA guidance raised to $33M-$35M; revenue guidance reiterated at $205M-$215M.
Opened GMP enzyme manufacturing facility; ModTail product line has 125+ active customers including leading biopharma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.